Bayer Aktiengesellschaft (OTCMKTS:BAYRY) Stock Price Down 5.8% – Should You Sell?

Bayer Aktiengesellschaft (OTCMKTS:BAYRY) shares traded down 5.8% during trading on Wednesday . The company traded as low as $10.32 and last traded at $10.33. 292,773 shares were traded during mid-day trading, a decline of 77% from the average session volume of 1,284,280 shares. The stock had previously closed at $10.97.

Analyst Upgrades and Downgrades

BAYRY has been the topic of several research reports. DZ Bank downgraded Bayer Aktiengesellschaft from a “strong-buy” rating to a “strong sell” rating in a research report on Wednesday, February 18th. JPMorgan Chase & Co. upgraded Bayer Aktiengesellschaft from a “neutral” rating to an “overweight” rating in a research note on Monday, December 8th. Morgan Stanley upgraded Bayer Aktiengesellschaft from an “equal weight” rating to an “overweight” rating in a research report on Wednesday, December 3rd. Zacks Research downgraded Bayer Aktiengesellschaft from a “strong-buy” rating to a “hold” rating in a report on Monday, February 23rd. Finally, Barclays upgraded shares of Bayer Aktiengesellschaft from an “equal weight” rating to an “overweight” rating in a research note on Tuesday, January 6th. Two equities research analysts have rated the stock with a Strong Buy rating, four have given a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy”.

Bayer Aktiengesellschaft Stock Performance

The stock has a 50 day moving average of $12.42 and a 200 day moving average of $9.87. The company has a quick ratio of 0.71, a current ratio of 1.14 and a debt-to-equity ratio of 1.10. The firm has a market cap of $43.03 billion, a price-to-earnings ratio of -121.65, a P/E/G ratio of 4.67 and a beta of 0.69.

Bayer Aktiengesellschaft Company Profile

Bayer Aktiengesellschaft is a global life sciences company headquartered in Leverkusen, Germany, with a history dating back to 1863. The company operates across three principal business areas—Pharmaceuticals, Consumer Health and Crop Science—serving customers and markets worldwide. Bayer develops, manufactures and markets prescription medicines, over-the-counter healthcare products and agricultural solutions, and maintains research and development programs focused on new therapies and technologies in its core fields.

In Pharmaceuticals, Bayer focuses on prescription drugs across therapeutic areas such as cardiology, oncology, hematology and women’s health, supporting clinical development and regulatory activities for both marketed products and pipeline candidates.